Koblin BA, Metzger D, Sheon A, Critchlow C, Heagerty P; International Conference on AIDS.
Int Conf AIDS. 1996 Jul 7-12; 11: 35 (abstract no. We.C.215).
New York Blood Center, New York, NY. Fax: (212) 570-3385.
Objective: To assess the readiness of U.S. high-risk populations to participate in HIV vaccine efficacy trials. Methods: Data collected at baseline visit from 3272 gay men (GM)826 male IDUs346 female IDUs and 488 women at increased sexual risk but no IDU history (HxF) recruited in 7 cities of the Vaccine Preparedness Study of the HIV Prevention Trial Network (HIVNET). Willingness to participate in future trials factors influencing willingness and knowledge about vaccine trials were compared across demographic and risk behaviors. Results: Overall77% thought they would be willing to participate in future trials (27% definitely willing 50% probably 18% probably not 5% definitely not). Using multiple regression comparing those definitely willing to all others HxF were more willing compared to GM (OR=1.3); male IDUs were less willing (OR=0.8). Willingness was higher with lower educational level and among those with no health insurance vs. those with private insurance (OR=1.4). Participants who had been in previous HIV studies were less willing (OR=0.6). Willingness was not related to frequency of unprotected sex but was higher with higher frequency of needle sharing. The factors which most participants endorsed as 'very important' in willingness to participate were 'helping to find a vaccine' (72%) and 'helping to stop the epidemic' (69%). The factors least likely to be ranked 'very important' were getting money for visits (9%) fear that others would think the participant is high risk (9%) and fear of being avoided (6%). For the knowledge test the overall mean no. of correct items was 6.5 of 14. Knowledge was highest among GM those from previous studies those most educated and those with private health insurance but was not related to risk behaviors. Among each risk group lower knowledge was associated with greater willingness. Conclusions: A large proportion of these high-risk populations are willing to participate in future trials although further education is needed on vaccine trial design issues.
Publication Types:
Keywords:
- AIDS Vaccines
- Acquired Immunodeficiency Syndrome
- Clinical Trials as Topic
- Female
- HIV Infections
- HIV Seropositivity
- Homosexuality, Male
- Humans
- Male
- Research Design
- Risk-Taking
- United States
- Unsafe Sex
Other ID:
UI: 102219154
From Meeting Abstracts